Daniel McGilvray, DO
Family Medicine · Fort Worth, TXNPI 1386965234
Payments from drug & device makers
Across 347 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- GSK$1K
- Lilly USA, LLC$818
- Novo Nordisk$692
- AstraZeneca$635
- Boehringer Ingelheim$404
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 20 | $1,215 |
| GSK | 57 | $1,024 |
| Lilly USA, LLC | 46 | $818 |
| Novo Nordisk | 39 | $692 |
| AstraZeneca | 26 | $635 |
| Boehringer Ingelheim | 22 | $404 |
| Pfizer | 25 | $352 |
| AbbVie(2 entities) | 19 | $332 |
| Dexcom, Inc. | 7 | $244 |
| Sanofi-aventis U.S. LLC | 11 | $200 |
| Bayer | 8 | $195 |
| Novartis | 6 | $139 |
| Exact Sciences | 8 | $129 |
| Astellas Pharma US Inc | 6 | $104 |
| Johnson & Johnson | 5 | $87 |
| Inspire Medical Systems, Inc. | 1 | $82 |
| Merck | 5 | $70 |
| Shire North American Group Inc | 4 | $54 |
| Amarin Pharma, Inc. | 3 | $52 |
| Gilead | 3 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Amgen | 3 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $44 |
| Corcept Therapeutics | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Evofem Biosciences, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $23 |
| Globus Medical | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$581
- FreeStyle Libre$304
- FreeStyle Libre 2$136
- DEXCOM G6 TRANSMITTER$136
- AREXVY$122
- SHINGRIX$120
- AIRSUPRA$110
- Kerendia$101
How this compares
$7,347 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 183 | $240,462 |
| MounjaroTirzepatide | 64 | $78,750 |
| JardianceEmpagliflozin | 51 | $60,208 |
| EliquisApixaban | 51 | $54,854 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 41 | $41,452 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $40,655 |
| FarxigaDapagliflozin Propanediol | 13 | $18,266 |
| JanuviaSitagliptin Phosphate | 22 | $17,725 |
| MyrbetriqMirabegron | 12 | $13,183 |
| Atorvastatin Calcium | 602 | $4,909 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $4,406 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 43 | $3,728 |
| Rosuvastatin Calcium | 335 | $3,714 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $3,385 |
| Omeprazole | 158 | $3,149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $692 | $240,462183 claims |
| Lilly USA, LLCMounjaro | $818 | $78,75064 claims |
| Boehringer IngelheimJardiance | $404 | $60,20851 claims |
| PfizerEliquis | $352 | $54,85451 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $200 | $41,45241 claims |
| GSKTrelegy Ellipta | $1,024 | $40,65554 claims |
| AstraZenecaFarxiga | $635 | $18,26613 claims |
| MerckJanuvia | $70 | $17,72522 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $13,18312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- William SegerFort Worth$27.5M
- Mark KochFort Worth$7.6M
- Isaac WatembergFort Worth$3.2M
- James HarveyFort Worth$2.7M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.